Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. The company has a research collaboration with Virginia Tech Carilion School of Medicine to examine long-term recovery in individuals with moderate to severe opioid use disorder that received at least one dose of study treatment during the SUBLOCADE Phase 3 clinical trials. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.